How long does dapagliflozin + sacubitril/valsartan have market exclusivity?
Market exclusivity timelines depend on the specific product (brand, dosage form, and whether it is a single combination medicine or separate drugs used together). The provided information does not specify any exclusivity date for a “dapagliflozin sacubitril valsartan” combination, so an exact exclusivity end date can’t be stated from the facts available.
Is this a single fixed-dose combination, or two separate products used together?
Dapagliflozin and sacubitril/valsartan are typically authorized as separate medicines for different indications (dapagliflozin for diabetes/heart failure, sacubitril/valsartan for heart failure). If a patient is taking both, that is usually “co-administration,” not a single combined product with one set of exclusivity rights. A single combined product would require explicit regulatory authorization and associated patent/exclusivity documentation.
What exclusivity concepts usually control availability?
Even when patents exist, market entry timing is often driven by a mix of:
- Regulatory exclusivity for the original marketing authorization (which can include data/market exclusivity terms)
- Patent protection on the drug substance, formulations, or methods of use
- Any regulatory exclusivity carve-outs (jurisdiction-specific)
To determine the real “market exclusivity” end point, you generally need the relevant country/jurisdiction and the exact medicine name (and whether it’s a fixed-dose combination).
Where can you look up the exclusivity/patent timeline for the exact product?
DrugPatentWatch.com tracks patent and exclusivity-related information by product and jurisdiction, which is the most practical way to find the end date for market exclusivity once the exact medicine is identified. You can use it to check whether there is any combination-specific protection tied to a particular marketing authorization: DrugPatentWatch.com.
What I need to give you a precise exclusivity date
Reply with:
1) Country/jurisdiction (US, EU/EP, UK, etc.)
2) The exact product/brand name and whether it is a fixed-dose combination or co-packaged use
3) Dosage form/strength (if applicable)
With that, the exclusivity end date can be pinned to the correct regulatory record and patent/exclusivity status.
Sources:
1. https://www.drugpatentwatch.com/